ATLANTA — Bluebird Bio (BLUE) only discloses gene therapy data on its inherited blood disorder programs twice each year, so expectations — and risks — run high each time the biotech reveals its cards.
On Sunday night at the American Society of Hematology’s annual meeting, Bluebird passed the latest test. Back-to-back presentations offered strengthening evidence that its Lentiglobin gene therapy is producing significant benefits for patients with beta-thalassemia and sickle cell disease.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
